Brain levels of neuropeptides in human chronic methamphetamine users

Neuropharmacology

Volumn 53, Issue 3, 2007, Pages 447-454

  Frankel, Paul S ^a   Alburges, Mario E ^a   Bush, Lloyd ^a   Hanson, Glen R ^a   Kish, Stephen J ^b  

^a UNIVERSITY OF UTAH   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Drug abuse; Dynorphin; Human; Methamphetamine; Neuropeptide Y; Neurotensin

Indexed keywords

DOPAMINE; DYNORPHIN; METENKEPHALIN; METHAMPHETAMINE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; SUBSTANCE P;

ADULT; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN TISSUE; CAUDATE NUCLEUS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ABUSE; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM EXPOSURE; MALE; NEUROENDOCRINE SYSTEM; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; RADIOIMMUNOASSAY;

ADULT; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METHAMPHETAMINE; NEUROPEPTIDES; POSTMORTEM CHANGES; RADIOIMMUNOASSAY; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS;

EID: 34547664712     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.009     Document Type: Article

References (42)

1. Adams D.H., Hanson G.R., and Keefe K.A. Differential effect of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience 102 (2001) 843-851
2. Alburges M.E., Keefe K.A., and Hanson G.R. Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model. Journal of Neurochemistry 76 (2001) 721-729
3. Anderson K.D., and Reiner A. Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionary conserved feature of basal ganglia organization. Journal of Comparative Neurology 295 (1990) 339-369
4. Castel M.N., Morino P., Frey P., Terenius L., and Hokfelt T. Immunohistochemical evidence for a neurotensin pathway in the rat brain. Neuroscience 55 (1993) 833-847
5. Castellani S., Giannini A.J., and Adams P.M. Effects of naloxone, metenkephalin, and morphine on phencyclidine-induced behavior in the rat. Psychopharmacology 78 (1982) 76-80
6. Chapman M., See R., and Bissett G. Neurotensin increases striatal dopamine levels in vivo. Neuropeptides 3 (1992) 175-183
7. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh E.W., Hsiao C.C., Chiang Y.L., Ree S.C., Lee C.H., and Murray R.M. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine 33 (2003) 1407-1414
8. Ervin G.N., Birkemo L.S., Nemeroff C.B., and Prange A.J. Neurotensin blocks certain amphetamine-induced behaviors. Nature 291 (1981) 73-76
9. Frankel P.S., Hoonakker A.J., Hanson G.R., Bush L., Keefe K.A., and Alburges M.E. Differential neurotensin responses to low and high doses of methamphetamine in the terminal regions of striatal efferents. European Journal of Pharmacology 522 (2005) 47-54
10. 18F]FDG. Neuropsychopharmacology 20 (1999) 565-581
11. Hanson G.R., Merchant K.M., Letter A.A., Bush L., and Gibb J.W. Characterization of methamphetamine effects on the striatal-nigral dynorphin system. European Journal of Pharmacology 155 (1988) 11-18
12. Hanson G.R., Bush L.G., Taylor V.L., Gibb J.W., Davis K., and Schmidt C.J. Comparison of neurotensin responses to MDL 100,907, a selective 5-HT2A antagonist, with clozapine and haloperidol. Brain Research Bulletin 42 (1997) 211-219
13. Hanson G.R., Bush L., Keefe K.A., and Alburges M.E. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine. Journal of Neurochemistry 82 (2002) 1171-1178
14. Hurd Y.L., and Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13 (1993) 357-369
15. Johnson M., Bush L.G., Gibb J.W., and Hanson G.R. Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems. European Journal of Pharmacology 193 (1991) 367-370
16. Kalasinsky K.S., Bosy T.Z., Schmunk G.A., Reiber G., Anthony R.M., Furukawa Y., Guttman M., and Kish S.J. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Science International 116 (2001) 163-169
17. Kalasinsky K.S., Hugel J., and Kish S.J. Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). Journal of Forensic Science 49 (2004) 1106-1112
18. Kalivas P.W., and Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. American Journal of Psychiatry 162 (2005) 1403-1413
19. Kish S.J., Kalasinsky K.S., Furukawa Y., Guttman M., Ang L., Li L., Adams V., Reiber G., Anthony R.A., Anderson W., Smialek J., and DiStefano L. Brain choline acetyltransferase in chronic, human users of cocaine, methamphetamine, and heroin. Molecular Psychiatry 4 (1999) 26-32
20. Kleinman J.E., Hong J., Iadarola M., Govoni S., and Gillin G.J. Neuropeptides in human brain - postmortem studies. Progress in Neuro-psychopharmacology and Biological Psychiatry 9 (1985) 91-95
21. Letter A.A., Merchant K.M., Gibb J.W., and Hanson G.R. Effect of methamphetamine on neurotensin concentrations in rat brain regions. Journal of Pharmacology and Experimental Therapeutics 24 (1987) 443-447
22. London E.D., Berman S.M., Voytek B., Simon S.L., Mandelkern M.A., Monterosso J., Thompson P.M., Brody A.L., Geaga J.A., Hong M.S., Hayashi K.M., Rawson R.A., and Ling W. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biological Psychiatry 58 (2005) 770-778
23. Mai J.K., Paxinos G., and Assheuer J.K. Atlas of the Human Brain (2003), Academic Press, San Diego, CA
24. McLeman E.R., Warsh J.J., Ang L., Li P.P., Kalasinsky K.S., Ross B.M., Tong J., Schmunk G., Adams V., and Kish S.J. The human nucleus accumbens is highly susceptible to G protein down-regulation by methamphetamine and heroin. Journal of Neurochemistry 74 (2000) 2120-2126
25. Midgley L.P., Wagstaff J.D., Singh N.A., Bush L.G., Gibb J.W., and Hanson G.R. Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbal regions. European Journal of Pharmacology 251 (1994) 191-199
26. Mirecki A., Fitzmaurice P., Ang L., Kalasinsky K.S., Peretti F.J., Aiken S.S., Wikham D.J., Sherwin A., Nobrega J.N., Forman H.J., and Kish S.J. Brain antioxidant systems in human methamphetamine users. Journal of Neurochemistry 89 (2004) 1396-1408
27. Moszczynska A., Fitzmaurice P., Ang L., Kalasinsky K.S., Schmunk G.A., Perretti F.J., Aiken S.S., Wikham D.J., and Kish S.J. Why is parkinsonism not a feature of human methamphetamine users?. Brain 127 (2004) 363-370
28. Posnett D.N., McGrath H., and Tam J.P. A novel method for producing antipeptide antibodies. Journal of Biological Chemistry 261 (1988) 1719-1725
29. Reid M., Herrera-Marchitz M., Hokfelt T., Terenius L., and Ungerstedt U. Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P. European Journal of Pharmacology 147 (1988) 411-420
30. Riley H.A. An Atlas of the Basal Ganglia, Brainstem, and Spinal Cord (1943), Williams and Wilkins, Baltimore, MD
31. Rompre P., and Perron S. Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology 39 (2000) 1880-1892
32. Steiner H., and Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental Brain Research 123 (1998) 60-76
33. Tang F.I., Chiu T.H., and Wang Y. Electrochemical studies of the effects of substance P on dopamine terminals in the rat. Journal of Pharmacology and Experimental Therapeutics 152 (1998) 41-49
34. Toyoshi T., Ukai M., and Kameyama T. Opioid receptor agonists selective for mu and kappa receptors attenuate methamphetamine-induced behavioral sensitization in the mouse. Biological and Pharmaceutical Bulletin 19 (1996) 369-374
35. Ukai M., Toyoshi T., and Kemeyama T. Multidimensional behavioral analyses show dynorphin A-(1-13) modulation of methamphetamine-induced behaviors in mice. European Journal of Pharmacology 222 (1992) 7-12
36. Volkow N.D., Chang L., Wang G.-J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.-S., Logan J., Wong C., and Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry 158 (2001) 377-382
37. Wagstaff J.D., Gibb J.W., and Hanson G.R. Microdialysis of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 278 (1996) 547-554
38. Wagstaff J.D., Gibb J.W., and Hanson G.R. Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Research 721 (1996) 106-203
39. Westwood S.C., and Hanson G.R. Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems. Journal of Pharmacology and Experimental Therapeutics 288 (1999) 1160-1166
40. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., and Kish S.J. Striatal dopamine nerve terminal markers in human chronic methamphetamine users. Nature Medicine 6 (1996) 699-703
41. Winder D.G., Egli R.E., Schramm N.L., and Matthews R.T. Synaptic plasticity in drug reward circuitry. Current Molecular Medicine 2 (2002) 667-676
42. Zachariou V., Bolanos C.S., Selley D.E., Theobald D., Cassidy M.P., Kelz M.B., Shaw-Lutchman T., Berton O., Sim-Selley L.J., Dileone R.J., Kumar A., and Nestler E.J. An essential role for DeltaFosB in the nucleus accumbens in morphine action. Nature Neuroscience 9 (2006) 205-211